Zobrazeno 1 - 10
of 12
pro vyhledávání: '"David G. Hoel"'
Autor:
Morando, Soffritti, Eva, Tibaldi, Michela, Padovani, David G, Hoel, Livio, Giuliani, Luciano, Bua, Michelina, Lauriola, Laura, Falcioni, Marco, Manservigi, Fabiana, Manservisi, Fiorella, Belpoggi
Publikováno v:
American journal of industrial medicine. 59(7)
Experimental rodent bioassays performed up to now have failed to provide conclusive confirmation of the carcinogenicity of extremely low frequency magnetic fields (ELFMF).To evaluate the potential synergistic carcinogenic effects of concurrent exposu
Autor:
David G. Hoel, Christopher J. Portier
Publikováno v:
Environmental Health Perspectives
Carcinogenesis data for 315 chemicals were obtained from the National Cancer Institute-National Toxicology Program (NCI-NTP) bioassay programs and were analyzed to examine the shape of carcinogenesis dose-response curves. Tumor site data were more of
Publikováno v:
Risk Analysis. 12:115-121
The use of average qualitative concordance between two bioassay endpoints is considered, with emphasis directed at agreement between rats and mice from results of long-term carcinogenicity studies. It is noted that concordance varies as a function of
Publikováno v:
Fundamental and applied toxicology : official journal of the Society of Toxicology. 20(4)
Predictive Strategies for Selecting 379 NCI/NTP Chemicals Evaluated for Carcinogenic Potential: Scientific and Public Health Impact. Fung, V. A., Huff, J. H., Weisburger, E. K., and Hoel, D. G. (1993). Fundam. Appl. Toxicol. 20, 413-436. The a priori
Publikováno v:
Toxicology and Applied Pharmacology. 55:154-161
A general scheme is proposed which relates the carcinogenic responses to the amount of DNA-carcinogen adduct formed instead of applied dose. Based on the present understanding of the mechanism of carcinogenesis, we believe this to be a more rational
Autor:
David G. Hoel, Walter W. Piegorsch
Publikováno v:
Mutation Research/Reviews in Genetic Toxicology. 196:161-175
Salmonella mutagenic and rodent carcinogenic potencies are calculated for 112 compounds recently studied by the U.S. National Toxicology Program. 28 of the 112 compounds are seen to exhibit simultaneous non-zero mutagenic and carcinogenic potencies.
Autor:
Christopher J. Portier, David G. Hoel
Publikováno v:
Risk Analysis. 7:437-447
The TD50 (or tumorigenic dose rate 50) is a generally accepted measure of the carcinogenic potency of a chemical in a particular strain of animal. This paper discusses error in the estimation of the TD50 caused by intercurrent mortality and error res
Publikováno v:
Science. 219:1032-1037
Efforts in estimating carcinogenic risk in humans from long-term exposure to chemical carcinogens have centered on the problem of low-dose extrapolation. For chemicals with metabolites that interact with DNA, it may be more meaningful to relate tumor
Publikováno v:
Fundamental and Applied Toxicology. 5:79-86
In risk estimation, the results of rodent carcinogenesis experiments are often used to quantitatively predict effects in man. The justification for this approach has in large part been dependent upon the good correlation of carcinogenic potency found
Autor:
Christopher J. Portier, David G. Hoel
Publikováno v:
Toxicological Sciences. 4:949-959
The effect of bioassay design changes on the variability of risk estimates in the experimental dose region is investigated. Three-dose designs with a control group and other "usual" designs utilizing 200 animals are studied in detail. Constraints on